Remove 2026 Remove Biopharma Remove Competition
article thumbnail

CMS Touts First Negotiated Drug Prices, But Greater Impact Expected in Future Rounds

MedCity News

The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come.

article thumbnail

Trends in biopharma contract manufacturing 2022

European Pharmaceutical Review

However, China and India are set to be fierce competition over the next decade, with 30 percent of respondents suggesting they would offshore >50 percent of clinical trials and operations to India, China or other lower-cost countries over the next five years.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Sandoz to build Slovenian biosimilar development facility

European Pharmaceutical Review

The company intends to invest approximately $90 million at its site in Ljubljana, Slovenia, to establish a dedicated Sandoz Biopharma Development Center by 2026. They drive competition and cost savings, helping to address the rising financial pressures faced by global healthcare systems.

article thumbnail

Beyond transparent pricing: decoding the strategies of major PBMs

Clarivate

These moves mark a strategic shift towards greater transparency and predictability, driven by regulatory pressures and rising competition from market disruptors. Click here to learn more about how Clarivate helps biopharma companies navigate market access across global markets.

Retail 59
article thumbnail

Five points on CMS’s first ten picks for price negotiations

Clarivate

The initial list, which takes effect in 2026, has the potential to roil formularies since it includes a mix of high-volume, preferred brands and a group of high-cost specialty drugs for autoimmune conditions (psoriasis) and cancer. exclusions exist for orphan drug designation and biosimilar competition ).

article thumbnail

What a string of semaglutide biosimilars could mean for Mainland China

Clarivate

Competition is expected to intensify in the next few years as both Novo Nordisk and Eli Lilly plan to launch their respective weight-loss drugs in Mainland China. Robust clinical data around multiple cardiometabolic indicators supported by all three assets is poised to lead widespread adoption in Mainland China.

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. billion deal to acquire Oak Street Health, a value-based primary-care company focused on treating Medicare patients. In January 2023, VillageMD acquired Summit Health for $8.9